illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Alnylam Pharmaceuticals
Company logo

Alnylam Pharmaceuticals | Sustainability Performance

https://www.alnylam.com/

Discovers and develops RNA interference-based therapeutics.

2002

United States

1,001 - 5,000 employees

Biotechnology

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#269
Overallⓘ
#61
in United Statesⓘ
#4
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

154 out of 244

Overview
Environmental
Carbon emissionsEnergy consumptionWater ManagementNature and biodiversity
Social
Diversity and InclusionPay GapsExternalities
Governance
SDG Impact

View similiar companies

Company logo
Arcturus Therapeutics

United States, Health Care, Biotechnology

Company logo
Biomarin Pharmaceutical

United States, Health Care, Biotechnology

Company logo
Insmed

United States, Health Care, Biotechnology

CO2 scope 1 + 2 ⓘDirect emissions from owned or controlled sources, combined with indirect emissions from purchased electricity calculated using grid-average emission factors based on where the energy is consumed.
13.5KCO2e tonnes, 2024
Leading
Female employees ⓘProportion of women in the company's total workforce, expressed as a percentage.
54%2024
Aligned
Externalities ⓘThe monetized estimate of environmental and social impacts caused by an organization that are not reflected in its financial accounts.
846.3K$, 2024
Critical

Intensity

Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark

3.6

B/M 10.8

46.8

B/M 128.6

6.4

B/M 27.9


Powered by illuminem and GIST Impact

Reporting

Not reporting on Sustainability

image report
Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

    Available in
    Scale package

    Access
  • Email
  • Email